Not yet recruiting

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma

By April 24, 2017 One Comment

Condition

Pleural Mesothelioma Malignant Advanced

Estimated Enrollment: 142

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: ETOP 9-15|2016-002062-31|3475-594

Study First Received: December 9, 2016

Last Updated: December 9, 2016

Estimated Primary Completion Date: November 2020

 

Primary Outcome Measures:

Progression Free Survival (PFS) in patients with advanced pre-treated malignant mesothelioma.|Objective response.|Overall survival.|Time to treatment failure.|Toxicity/adverse events.|Investigator assessed PFS

Sponsors and Collaborators:

European Thoracic Oncology Platform|Merck Sharp & Dohme Corp.|Frontier Science Foundation, Hellas

Website Link: https://ClinicalTrials.gov/show/NCT02991482

One Comment

  • I have been reading your articles PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma – The Asbestos Cancer Organization and they are too much useful for me to read something new and special. And You can also view our web also paypal and ebay accounts.

Leave a Reply

Call Now